Abbonarsi

Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study - 28/10/21

Doi : 10.1016/j.clinre.2020.10.014 
Jean-Louis Legoux a, , Catherine Lombard-Bohas b, Hedia Brixi c, Karine Le Malicot d, Thierry Lecomte e, Laetitia Dahan f, Philippe Ruszniewski g, Abakar Mahamat-Abakar h, Pierre-Luc Etienne i, François-Xavier Caroli-Bosc j, Sophie Dominguez k, Bernard Paule l, Eric Terrebonne m, Pierre Michel n, Côme Lepage o, Gabriel Choukroun p

for Streptotox-FFCD0906 investigators1

  See supplementary appendix for the list of FFCD 0906 investigators/collaborators.

a Department of Hepato-Gastroenterology and Digestive Oncology, Hôpital de la Source, Orléans, France 
b Department of Medical Oncology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France 
c Department of Hepato-Gastroenterology, Hôpital Robert Debré, Reims, France 
d Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France 
e Department of Hepato-Gastroenterology and Digestive Oncology, Hôpital Trousseau, Tours, France 
f Department of Gastroenterology and Digestive Oncology, Hôpital la Timone, Marseille, France 
g Department of Gastroenterology, Hôpital Beaujon, Clichy, France 
h Department of Gastroenterology, Centre Hospitalier Universitaire, Nice, France 
i Department of Medical Oncology, Hôpital Privé des Côtes d'Armor, Plerin, France 
j Department of Gastroenterology, Centre Hospitalier Universitaire, Angers, France 
k Department of Digestive and Urologic Oncology, Centre Oscar Lambret, Lille, France 
l Department of Gastroenterology, Hôpital Paul Brousse, Villejuif, France 
m Department of Hepato-Gastroenterology, Hôpital du Haut-Lévêque, Pessac, France 
n Department of Hepato-Gastroenterology, Centre Hospitalier Universitaire, Rouen, France 
o Department of Hepato-Gastroenterology, Centre Hospitalier Universitaire, Dijon, France 
p Department of Nephrology Dialysis and Transplantation, and INSERM UMR 1088, Centre Hospitalier Universitaire, Amiens, France 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 10
Iconografia 3
Video 0
Altro 0

Highlights

This article on STZ-related nephrotoxicity describes one prospective and one retrospective cohort of patients with well-differentiated digestive neuroendocrine tumours.
The efficacy is on line with the previous series.
STZ toxicity was found to be mild when patients were given sufficient hydration before each injection and when doses were adapted in cases of biological renal abnormalities.
Only one grade 3-4 renal toxicity was described among the 111 patients.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Introduction

Streptozocin can impair renal function. The purpose of this study was to evaluate the evolution of renal function in patients receiving this anti-mitotic for the treatment of locally advanced/metastatic digestive well differentiated neuroendocrine tumours.

Methods

A prospective and a retrospective cohort of patients with normal baseline renal function were analysed. The primary endpoint was the incidence of a decrease in the estimated glomerular filtration rate ≥ 25% during treatment. Secondary endpoints were the evaluation of glomerular filtration rate changes, the impact of combined nephrotoxic treatments, other toxicities, compliance, and the objective response rate.

Results

After screening 142 patients, 27 were included in the prospective and 84 in the retrospective cohort. A decrease in estimated glomerular filtration rate ≥ 25% was observed in 32 patients (30%): respectively four (15.4%) and 28 patients (34.1%) among respectively 26 and 82 patients with numerous measures (P = 0.0097). Altogether, 39 patients (35%) experienced grade 1–2 renal toxicity, while no grade 3−4 occurred in the prospective and 1 occurred in the retrospective cohort. Renal toxicity was more frequent in the retrospective cohort with a less careful follow up. As best responses, objective response was achieved in 27% of patients with pancreatic primary tumours, disease control in 78.9% of patients with pancreatic primary tumours, in 87% of those with small bowel tumours and in 72.7% of patients with other primary locations.

Conclusions

Strongly recommended for pancreatic NET, streptozocin is associated with frequent mild renal toxicity but low occurrence of renal impairment in patients with baseline normal renal function and under adequate hydration.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Digestive neuroendocrine tumours, Renal function, Streptozocin

Abreviations : NETs, pNETs, STZ, eGFR, PC, RC, MDRD, OR, sbNETs


Mappa


© 2020  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 45 - N° 5

Articolo 101572- Settembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Positive histologic margins is a risk factor of recurrence after ileocaecal resection in Crohn’s disease
  • Clementine Riault, Momar Diouf, Denis Chatelain, Clara Yzet, Justine Turpin, Franck Brazier, Jean-Louis Dupas, Charles Sabbagh, Eric Nguyen-Khac, Mathurin Fumery
| Articolo seguente Articolo seguente
  • A study of leptin and its gene 2548 G/A Rs7799039 single-nucleotide polymorphisms in Egyptian children: A single-center experience
  • Amal Ahmed Mohamed, Hoda H. Ahmed, Sanaa M. ElSadek, Rasha S. Mohamed, Reham Y. El-Amir, Wafaa Salah, Eman Sultan, Dalia M. Abd El-Hassib, Hanan M. Fouad

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.